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BACKGROUND: High-sensitivity C-reactive protein predicts cardiovascular events in a wide range of clinical contexts.
However, the role of high-sensitivity C-reactive protein as a predictive marker for perioperative acute myocardial
infarction during noncardiac surgery is not yet clear. The present study investigated high-sensitivity C-reactive
protein levels as predictors of acute myocardial infarction risk in patients undergoing high-risk noncardiac surgery.
METHODS: This concurrent cohort study included patients aged $50 years referred for high-risk noncardiac surgery
according to American Heart Association/ACC 2002 criteria. Patients with infections were excluded.
Electrocardiograms were performed, and biomarkers (Troponin I or T) and/or total creatine phosphokinase and
the MB fraction (CPK-T/MB) were evaluated on the first and fourth days after surgery. Patients were followed until
discharge. Baseline high-sensitivity C-reactive protein levels were compared between patients with and without
acute myocardial infarction.
RESULTS: A total of 101 patients undergoing noncardiac surgery, including 33 vascular procedures (17 aortic and 16
peripheral artery revascularizations), were studied. Sixty of the patients were men, and their mean age was 66 years.
Baseline levels of high-sensitivity C-reactive protein were higher in the group with perioperative acute myocardial
infarction than in the group with non-acute myocardial infarction patients (mean 48.02 vs. 4.50, p=0.005). All five
acute myocardial infarction cases occurred in vascular surgery patients with high CRP levels.
CONCLUSIONS: Patients undergoing high-risk noncardiac surgery, especially vascular surgery, and presenting
elevated baseline high-sensitivity C-reactive protein levels are at increased risk for perioperative acute myocardial
infarction.
KEYWORDS: C-reactive protein; Noncardiac surgery; Cardiac risk in noncardiac surgery; Perioperative events;
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INTRODUCTION
Perioperative acute myocardial infarction (AMI) is seen in
less than 2% of patients undergoing noncardiac surgery in
nonselected series. In the United States, approximately 27
million patients undergo these procedures annually, and
approximately 8 million patients have coronary disease or
coronary risk factors.
1 Approximately one million cases of
perioperative cardiac complications, and 50,000 cases of
AMI are diagnosed annually, with significant morbimortal-
ity and medical costs.
2,3
Atherosclerosis has an inflammatory nature
4,5 and results
in thrombotic complications.
6 Inflammatory markers, such as
high-sensitivity C-reactive protein (hsCRP), are useful prog-
nostic factors for cardiovascular events in several situations,
independent of the traditional risk factors described in the
Framingham risk score.
7-13 The guidelines established by the
Center for Disease Control and Prevention and the American
Heart Association (AHA) in 2003 included hsCRP as a useful
tool for therapeutic decision-making in selected cases.
14
However, few studies have investigated whether hsCRP
levels might predict cardiac events in patients undergoing
noncardiac surgery,
15 and to this date, scores and guidelines
to evaluate risk factors for heart disease do not include the
analysis of hsCRP levels.
16-21 In only one report, a
prospective cohort study of patients undergoing peripheral
vascular surgery, a higher frequency of major cardiac events
was observed in patients with elevated hsCRP levels.
22,23
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773Thus, the present cohort study was designed to investi-
gate hsCRP levels as predictors of perioperative AMI during
high-risk noncardiac surgery.
METHODS
A concurrent cohort study was conducted to test for a
possible association between preoperative hsCRP levels and
perioperative AMI in patients undergoing high-risk non-
cardiac surgery. High-risk surgery, as defined by the ACC/
AHA 2002 guidelines, includes major, urgent surgeries,
particularly in elderly individuals; aortic or other major
vascular surgery; peripheral vascular surgery; and/or
prolonged surgeries associated with substantial fluid or
blood loss.
21 The study was conducted between March 2006
and July 2007 in two large hospitals in Porto Alegre (a state
capital in south Brazil) after approval from the Research
Ethics Committees of the two institutions. Male and female
patients over 50 years of age were included. Patients with
infections diagnosed during the previous two weeks and
those who had undergone endoscopic and/or video-
assisted surgery were excluded from the sample. Nine
patients refused to participate in the study, and three other
patients were excluded because their surgeries were
intraoperatively modified from major to minor procedures.
Patients were monitored with clinical follow-up electro-
cardiogram (ECG) and biomarker and/or cardiac enzyme
exams until discharge or until they were considered ready
for discharge. The investigators were unaware of preopera-
tive hsCRP levels until the study was concluded.
All patients signed an informed consent form.
Blood collection and laboratory methods
Anamnesis and electrocardiograms were obtained for all
patients. Peripheral blood samples were collected for
laboratory analyses (including hsCRP levels) at hospital
admission, on the day before surgery or immediately before
the surgical procedure. During follow-up, levels of troponin
I or T and/or total creatine phosphokinase (CK t) or CK-
myocardial band (CK-MB) were determined, and ECGs
were performed on the first and fourth mornings following
surgery. Additional ECGs and enzyme/biomarker analyses
were performed if needed. Clinical data were collected daily
until discharge.
All ECGs were analyzed by two independent cardiolo-
gists. Outcome analysis was performed by adjudicators
blinded to the hsCRP status.
The hsCRP concentration in serum or plasma samples
was determined by nephelometry in a central laboratory,
using standardized procedures and validated methodology.
The following reagents were used: VITROS Chemistry
Products (Ortho-Clinical Diagnostics, Inc. 100. Indigo
Creek Drive; Rochester, NY 14626-5101) hsCRP, 17
VITROS calibrator kit and FS VITROS Calibrator 1.
Troponin I or T levels were determined with a validated
technique, using the VITROS Troponin I reagent pack. In
some cases, the CPK-T and CPK-MB levels were determined
by dry chemistry analysis.
Definition of end points
The primary end point was perioperative AMI, defined
according to the consensus criteria of the Joint ESC/ACC
Committee 2000:
24
1. Increased Troponin I or T levels or an elevated CKT/
CK-MB relationship associated with at least one of the
following findings: development of new pathological Q
waves, ECG alterations suggestive of ischemia, need for
coronary interventions, or ischemic symptoms, or
2. Pathological findings suggestive of AMI.
Secondary end points included noncardiac death, minor
outcomes (including acute atrial fibrillation, acute decom-
pensation of cardiac heart failure (HF), bronchopneumonia,
acute renal failure, thromboembolic events and infection/
dehiscenceofthesurgicalwound),andlengthofhospitalstay.
Statistical analysis
SPSS v15.0 software was used for the analyses.
Quantitative variables are presented as means and standard
deviationsor medians and interquartile intervals. Categorical
variables are presented as proportions with 95% confidence
intervals. The Mann-Whitney test was used to evaluate
differences in CRP levels between patients with events and
those without. In addition, ROC curves were used to
determine the best CRP cutoffs that predicted events.
Categorical variables were analyzed using the chi-squared
test, and the relationship between CRP levels and length of
hospital stay was evaluated with the Spearman correlation.
Forallanalyses,resultswere consideredsignificantifp,0.05.
Concentrations of hsCRP, gender, age and the Cardiac
Risk Index for major surgery (CRI) (20) were included in a
forward stepwise multivariable logistic regression model.
RESULTS
The characteristics and risk profiles of the 101 patients (60
men) included in the study are presented in Table 1. The
patients’ mean age was 66 years.
Surgical procedures (n=101) included 33 vascular (17
aortic and 16 peripheral artery revascularizations), 29
orthopedic, 33 abdominal (including three cases of liver
transplantation), three thoracic and three neurological
Table 1 - Baseline characteristics of the study population.
Characteristic N (%)
Age (mean ¡ SD) 66¡59
Males (n, %) 60 (59.4)
Type of surgery (n, %)
Peripheral vascular 16 (15.8)
Aortic 17 (16.8)
Orthopedic 29 (28.7)
Abdominal 33 (32.6)
Thoracic 3 (2.9)
Neurological 3 (2.9)
CD history (n, %) 25 (24.7)
Cerebrovascular disease
history (n, %)
12 (11.88)
DM/insulin history (n, %) 11 (10.89)
HF history (n, %) 11 (10.89)
CRF (creatinine .2) (n, %) 7 (6.93)
Statin use (n, %) 36 (35.6)
Beta-blocker use (n, %) 51 (50.5)
Length of surgery (min)
(mean ¡ SD)
297.6 (285¡105.2)
Length of hospital stay (days)
(median ¡ IQI 25-75)
8 (7-15)
CD: coronary disease; DM: diabetes mellitus; HF: heart failure;
CRF: chronic renal failure; IQI: interquartile interval.
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aortic aneurisms).
Baseline hsCRP levels in the groups with and without
outcomes are presented in Table 2. Median hsCRP levels were
48.02 (14.02-230.12) and 4.50 (2.24-16.83) in patients with and
without AMI, respectively (p=0.005). Ten patients showed
hsCRP levels above 100 mg/L. Of these patients, two had
major events during follow-up (20%), compared with 3.3% in
the group with hsCRP levels ,100 mg/L (p=0.075).
All five AMI cases occurred in vascular surgery patients
with high CRP levels. When examining only vascular
surgery patients, the association between CRP levels and
AMI remained significant (p=0.018). During logistic regres-
sion, the CRP level remained significant (OR 12.1 p=0.025),
but vascular surgery showed marginal significance
(OR=5.6, p=0.05).
High sensitivity CRP levels were similar in the group of
patients with noncardiac deaths and those without, as well
as for minor outcomes (p .0.05) (Table 2).
A positive, statistically significant relationship was
observed between hsCRP levels greater than 10 mg/L and
longer hospital stay compared with patients with levels
under 10 mg/L (r=0.32 and p=0.001).
Table 3 presents the relative and absolute risks according
to hsCRP levels ,10 mg/L and $10 mg/L, as well as
diagnostic properties based on this cut-off point. High
sensitivity CRP’s sensitivity for predicting perioperative
AMI was 100%, with high specificity (68%) and a high
negative predictive value (.99%).
No associations were observed between perioperative
AMI incidence and gender or use of beta-blockers and/or
statins. Additionally, hsCRP levels did not differ according
to beta-blocker/statins use or CRI (20).
In the bivariable analysis, CRI was significantly associated
with the incidence of AMI (p=0.028 for linear association). In
the multivariable logistic regression analysis, however, hsCRP
levels $10 remained the only independent predictors of
perioperative AMI (RC 14.27, p=0.017) after adjusting for CRI,
gender and age. Table 4 shows the odds ratios of MACE for
patients with hsCRP levels $10, adjusted by CRI. The results
were reanalyzed after excluding 10 patients with suspected
collagenosis, recent fever, bleeding for more than one day,
invasive neoplasia or toe necrosis; all of these patients had
hsCRPlevels.100 mg/L. However, the results were similar to
those obtained in the first analysis, in which the exclusion
criteria were restricted to diagnosed infection, either active or
within the previous two weeks (data not shown).
DISCUSSION
In this prospective study, high hsCRP levels were
significantly associated with an increased risk of periopera-
tive AMI.
In a recent prospective study of patients undergoing
peripheral vascular surgery, Owens and colleagues
22
showed similar results, demonstrating that high hsCRP
levels (.5 mg/L) were associated with cardiac events and
graft complications.
It is important to differentiate this clinical context from
hsCRP levels .1 mg/L, which are associated with low grade,
chronic inflammation that represents a higher cardiac risk in
long-term studies. Such levels are useful for evaluating
cardiac risk in clinical practice (hsCRP levels from 1 to 3 and
.3 mg/L represent medium and high risk, respectively).
Concentrations .10 are usually considered indicative of
acute inflammatory processes and should be confirmed with
retesting after 2 weeks.
14 Ridker and colleagues, however,
suggested, that extremely high hsCRP levels may be useful
for predicting cardiovascular disease and thrombotic
events,
25 as observed in the present study.
The high incidence of perioperative AMI and noncardiac
deaths in our sample may be due to a combination of factors.
Patients included in the sample had a .5% probability of AMI
and cardiac deaths according to AHA/ACC 2002 criteria,
which categorized them as high-risk surgery patients.
Furthermore, their mean age was elevated (66 years), and they
underwent urgent and even emergency procedures. With the
significant evolution of endovascular and video-laparoscopic
procedures, high-risk noncardiac surgery is currently per-
formed only in the most severe cases with extensive disease and
Table 2 - Median and quartiles of CRP levels in the groups
with and without events
hsCRP (median, Q1-Q3) P
AMI (n=5) Yes 48.02 (14.02-230.12) 0.005
No 4.50 (2.24-16.83)
Noncardiac death
(n=6)
Yes 2.91 (1.72-5.11) 0.130
No 5.58 (2.33-20.96)
Minor outcomes
(n=39)*
Yes 7.59 (2.63-38.29) 0.076
No 4.50 (2.00-13.42)
AMI: acute myocardial infarction; Q1; first quartile; Q3: third quartile;
hsCRP: high-sensitivity C-reactive protein.
*Minor outcomes: atrial fibrillation, acute heart failure, surgical wound
infection, bronchopneumonia, thromboembolic events.
Table 3 - Relative risk, absolute risk, sensitivity, specificity, and positive and negative predictive values for the cut-off
point of $10 mg/L hsCRP.
% events
,10 hsCRP $10 hsCRP
RR
(95% CI)
AR
(95%) P
#ROC
(95% CI) S Sp +PV -PV
AMI 0 13.9 - 13.9
(7.23-20.77)
0.005 0.85
(0.74-0.96)
100.0 67.7 13.9 100.0
Noncardiac death 9.2 0 - - 0.096 0.32
(0.16-0.47)
- 62.1 - 90.8
Minor outcomes 33.8 47.2 1.4
(0.9-2.3)
13.4
(7.24-19.56)
0.206 0.61
(0.49-0.72)
43.6 69.4 47.2 66.2
AMI: acute myocardial infarction; hsCRP: high-sensitivity C-reactive protein in mg/L; RR: relative risk; PV: predictive value; AR: Absolute risk; ROC: area
under the curve; S: sensitivity; Sp: specificity.
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sample presented invasive tumors and/or extensive vascular
atherosclerosis. Approximately half of the patients presented
two or more CRI predictors.
20
In our sample, as previously reported in similar studies,
CRI adequately classified the patients according to their risk
of major cardiac complications. Perioperative AMI occurred
in 25% of the patients with CRI $3 versus 1.2% of patients
with CRI ,2 (p=0.002).
Perioperative AMI occurred during the first days after
surgery, with four cases during the first 24 hours. None of
the cases had ST-segment elevation, emphasizing the need
to discuss routine postoperative care and screening. Because
there is no routine analysis of biomarkers and/or cardiac
enzymes in this type of surgery, two cases would have had
delayed diagnoses. Two patients underwent percutaneous
coronary intervention, one patient underwent CABG, and
two patients received clinical treatment.
Some limitations of our study included the small absolute
number of events and the relatively short follow-up, which
included only the hospitalization period. However, because
our main objective was to improve the in-hospital care of
these patients, it is important to consider that our significant
events were precisely those events that occur early in the
intra- or postoperative period.
Our results suggest that there is a role for baseline hsCRP in
predicting perioperative AMI in patients undergoing high-risk
noncardiac surgery. Patients presenting with high hsCRP levels
(.10 mg/L) could benefit from more rigorous preoperative
assessment and careful postoperative follow-up. Interventions
that reduce inflammation before surgery may also be helpful.
Interestingly, recent studies have shown beneficial effects of
statins in vascular surgery,
26,27 emphasizing this idea. Further
studies are necessary to define the clinical impact and cost-
effectiveness of including hsCRP levels in the scores for
predicting cardiac risk during noncardiac surgery.
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